reports
Cardiff Oncology Reports First Quarter 2024 Results and Provides Busin...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib’s antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvansertib’s acti...
Oxford Square Capital Corp. Announces Net Asset Value and Selected Fin...
Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended March 31, 2024 and Declaration of Distributions on Common Stock for the Months Ending July 31, August 31, and September 30, 2024 GREENWICH, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended March 31, 2024. On April 25, 2024, our Board of Directors declared the following distributions on our com...
Oxford Square Capital Corp. Schedules First Quarter 2024 Earnings Rele...
Oxford Square Capital Corp. Schedules First Quarter 2024 Earnings Release and Conference Call for May 2, 2024 GREENWICH, Conn., April 26, 2024 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) announced today that it will hold a conference call to discuss first quarter 2024 earnings on Thursday, May 2, 2024 at 9:00 AM Eastern time. The toll free dial-in number is 1-800-445-7795, verbal access code is OXFORD. There will be a recording available for 30 days after the call. If you are interested in hearing the recording, please dial 1-877-693-42...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Busi...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update - Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast ...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meetin...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onva...
Oxford Square Capital Corp. Announces Net Asset Value and Selected Fin...
Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended December 31, 2023 and Declaration of Distributions on Common Stock for the Months Ending April 30, May 31, and June 30, 2024. GREENWICH, Conn., March 15, 2024 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended December 31, 2023. On March 14, 2024, our Board of Directors declared the following distributions on our c...
Oxford Square Capital Corp. Schedules Fourth Quarter 2023 Earnings Rel...
Oxford Square Capital Corp. Schedules Fourth Quarter 2023 Earnings Release and Conference Call for March 15, 2024 GREENWICH, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: ) (NasdaqGS: OXSQZ) (NasdaqGS: OXSQG) announced today that it will hold a conference call to discuss fourth quarter 2023 earnings on Friday, March 15, 2024 at 9:00 AM Eastern time. The toll free dial-in number is 1-833-470-1428, access code number 451853. There will be a recording available for 30 days after the call. If you are interested in hearing the recording, please dial 1-866-813...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual M...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California. “The posters we will be presenting at this year’s AACR meeting represent a broad v...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024 - - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Cash and equivalents of $75 million as of...
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second...
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company discontinued the ONSEMBLE trial in August 2023 to shift focus of clinical development program to first-line RAS-mutated mCRC in agreement with the FDA - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWS...
Cardiff Oncology Announces First Patient Dosed in Randomized First-lin...
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) - Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the trial - - Initial topline results expected in mid-2024 – - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging ...
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Confe...
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024. Details of the fireside chat can be found below. Presenter: Mark Erlander, CEOD...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results a...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update - Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29 after the close of trading. Conference Call and We...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WTM WHITE MOUNTAINS INSURANCE GROUP LTD
TXRH TEXAS ROADHOUSE INC.
TNET TRINET GROUP INC.
MCY MERCURY GENERAL CORPORATION
EIG EMPLOYERS HOLDINGS INC.
CHEF CHEFS WAREHOUSE HOLDINGS
CAMT CAMTEK LTD.
QUAD QUAD/GRAPHICS INC. CLASS A
DNOW NOW INC.
GES GUESS? INC.
PVH PVH CORP.
USPH U.S. PHYSICAL THERAPY INC.
FONR FONAR CORP.
UIHC UNITED INSURANCE HOLDINGS CORP.
KNSL KINSALE CAPITAL GROUP INC.
TSEM TOWER SEMICONDUCTOR LTD
GLOB GAZIT-GLOBE LTD.
NOTV INOTIV INC
ABSI ABSCI CORP
RXST RXSIGHT INC
BLZE BACKBLAZE INC
COIN COINBASE GLOBAL INC
SERA SERA PROGNOSTICS INC
WGS ONTO INNOVATION INC.
BGC GENEDX HOLDINGS CORP.
DAVE BGC GROUP INC
VNOM DAVE INC
VIPER ENERGY INC
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
OPK OPKO HEALTH INC.
OCUL OCULAR THERAPEUTIX
LPSN LIVEPERSON INC.
FLO FLOWERS FOODS INC.
FDX FEDEX CORPORATION
DLTR DOLLAR TREE INC.
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
CYAN CYANOTECH
FIZZ NATIONAL BEVERAGE CORP.
PKTX PROTOKINETIX INC
CMXC CELL MEDX
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
HPK FABIEN CORP
ATHA HIGHPEAK ENERGY INC (A)
HQI ATHIRA PHARMA
AGL HIREQUEST INC.
TCRX AGILON HEALTH
BCAB INC.
MPA FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
SLDB BIOATLA INC
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
- Jonathan Moreland
OCUL OCULAR THERAPEUTIX
I3N CHART INDUSTRIES INC.
FLO FLOWERS FOODS INC.
FDX FEDEX CORPORATION
FATE FATE THERAPEUTICS INC
DLTR DOLLAR TREE INC.
CTSO CYTOSORBENTS
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ASA ASA
HRTG HERITAGE INSURANCE HOLDINGS INC.
ADC AGREE REALTY CORPORATION
CYAN CYANOTECH
FIZZ NATIONAL BEVERAGE CORP.
PKTX PROTOKINETIX INC
CDMO AVID BIOSERVICES
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
RBB INC.
VRCA RBB BANCORP
LOVE VERRICA PHARMACEUTICALS
AOUT LOVESAC
HPK AMERICAN OUTDOOR BRANDS
HQI INC.
TCRX HIGHPEAK ENERGY INC (A)
BCAB HIREQUEST INC.
TSE FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
TBBK BIOATLA INC
NWGID TRINSEO PLC
BPRN THE BANCORP
CUBA INC.
MBRX ELYS GAME TECHNOLOGY CORP
GURE BANK OF PRINCETON
LSXMA THE HERZFELD CARIBBEAN BASIN FUND
LSXMK INC.
MOLECULIN BIOTECH INC
GULF RESOURCES INC
LIBERTY SIRIUSXM GROUP
- Jonathan Moreland
OCUL OCULAR THERAPEUTIX
I3N CHART INDUSTRIES INC.
FLO FLOWERS FOODS INC.
FDX FEDEX CORPORATION
FATE FATE THERAPEUTICS INC
DLTR DOLLAR TREE INC.
DEA EASTERLY GOVERNMENT PROPERTIES INC
CTSO CYTOSORBENTS
ASYS AMTECH SYSTEMS INC.
ASA ASA
HRTG HERITAGE INSURANCE HOLDINGS INC.
ADC AGREE REALTY CORPORATION
PLAB PHOTRONICS INC.
CYAN CYANOTECH
FIZZ NATIONAL BEVERAGE CORP.
JFR NUVEEN FLOATING RATE INCOME FUND
PKTX PROTOKINETIX INC
CDMO AVID BIOSERVICES
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
KDP KEURIG DR PEPPER INC.
RBB RBB BANCORP
VRCA VERRICA PHARMACEUTICALS
CHWY CHEWY
AOUT INC.
HPK AMERICAN OUTDOOR BRANDS
ATHA INC.
HQI HIGHPEAK ENERGY INC (A)
NOTV ATHIRA PHARMA
MYO HIREQUEST INC.
TCRX INOTIV
BCAB INC.
TSE MYOMO
TBBK FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
NWGID BIOATLA INC
BPRN TRINSEO PLC
CUBA THE BANCORP
MBRX INC.
GURE ELYS GAME TECHNOLOGY CORP
BANK OF PRINCETON
THE HERZFELD CARIBBEAN BASIN FUND
INC.
MOLECULIN BIOTECH INC
GULF RESOURCES INC
- Jonathan Moreland
OCUL OCULAR THERAPEUTIX
FLO FLOWERS FOODS INC.
DLTR DOLLAR TREE INC.
ASYS AMTECH SYSTEMS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
UEIC UNIVERSAL ELECTRONICS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
CYAN CYANOTECH
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
DMLP DORCHESTER MINERALS L.P.
CDMO AVID BIOSERVICES
SNCR SYNCHRONOSS TECHNOLOGIES
AXR INC.
VRCA AMREP
ZM VERRICA PHARMACEUTICALS
CHWY ZOOM VIDEO COMMUNICATIONS
XAIR INC.
VTN CHEWY
AOUT INC.
HQI BEYOND AIR
AUID INVESCO TRUST FOR INVESTMENT G
TCRX AMERICAN OUTDOOR BRANDS
BCAB INC.
ATXS HIREQUEST INC.
TSE IPSIDY INC.
NWGID FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
CUBA BIOATLA INC
ASTRIA THERAPEUTICS INC
TRINSEO PLC
ELYS GAME TECHNOLOGY CORP
THE HERZFELD CARIBBEAN BASIN FUND
INC.
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.